HSP90AA1 and adrenal cortex carcinoma: Preclinical in-vitro and in-vivo studies were performed to validate the synergistic efficacy of the most effective HSP90 inhibitor and PI3K inhibitor combination in ACC cell lines, human ACC xenografts and patient-derived organoids (PDOs).